FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2763344034> ?p ?o ?g. }

• W2763344034 endingPage "105114" @default.
• W2763344034 startingPage "105103" @default.
• W2763344034 abstract "// Simon Baldacci 1, 15 , Julien Mazieres 2 , Pascale Tomasini 3 , Nicolas Girard 4 , Florian Guisier 5 , Clarisse Audigier-Valette 6 , Isabelle Monnet 7 , Marie Wislez 8 , Maurice Pérol 9 , Pascal Dô 10 , Eric Dansin 11 , Charlotte Leduc 12 , Etienne Giroux Leprieur 13 , Denis Moro-Sibilot 14 , David Tulasne 15 , Zoulika Kherrouche 1, 15 , Julien Labreuche 16 and Alexis B. Cortot 1, 15 1 CHU Lille, Thoracic Oncology Department, Univ. Lille, Siric ONCOLille, Lille, France 2 Toulouse University Hospital, Université Paul Sabatier, Toulouse, France 3 Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations Department, Marseille, France 4 Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France 5 Rouen University Hospital, Thoracic oncology unit & Normandy University, IRIB, LITIS Lab, EA 4103 QuantIF team, Rouen, France 6 Service de Pneumologie, Centre Hospitalier Sainte Musse, Toulon, France 7 Centre Hospitalier Intercommunal de Créteil, Créteil, France 8 APHP Hôpital Tenon, Paris, France 9 Department of Medical Oncology, Centre Léon Bérard, Lyon, France 10 Centre Régional de Lutte Contre le Cancer François Baclesse, Caen, France 11 Centre Oscar Lambret, Lille, France 12 CHU Strasbourg, Strasbourg, France 13 APHP – Hôpital Ambroise Paré, Boulogne-Billancourt, France 14 Unité d’Oncologie Thoracique, Service de Pneumologie, CHU Grenoble-Alpes, La Tronche, France 15 Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161, M3T, Mechanisms of Tumorigenesis and Targeted Therapies, Lille, France 16 EA 2694 University of Lille, Lille, France Correspondence to: Alexis B. Cortot, email: alexis.cortot@chru-lille.fr Keywords: non small cell lung cancer; EGFR; tyrosine kinase inhibitors; resistance; MET Received: February 21, 2017     Accepted: August 04, 2017     Published: October 09, 2017 ABSTRACT Background: Several mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC have been described including the T790M mutation and MET amplification. Whereas T790M mutation confers prolonged survival and sensitivity to 3rd generation TKIs, data are lacking on clinical features and outcome of MET-driven resistant EGFR-mutated NSCLC patients. Methods: Patients with metastatic EGFR-mutated NSCLC displaying high MET overexpression or MET amplification, detected on a biopsy performed after progression on EGFR TKI, were identified in 15 centers. Clinical and molecular data were retrospectively collected. Results: Forty two patients were included. The median overall survival (OS), and the median post EGFR TKI progression overall survival (PPOS) were 36.2 months [95%CI 27.3-66.5] and 18.5 months [95%CI 10.6-27.4] respectively. Nineteen out of 36 tumors tested for MET FISH had MET amplification. A T790M mutation was found in 11/41 (26.8%) patients. T790M-positive patients had a better OS than T790M-negative patients (p=0.0224). Nineteen patients received a MET TKI. Objective response was reported in 1 out of 12 evaluable patients treated with a MET inhibitor as a single agent and in 1 of 2 patients treated with a combination of MET and EGFR TKIs. Conclusion: MET-driven resistance to EGFR TKI defines a specific pattern of resistance characterized by low objective response rate to MET inhibitors given alone and overlapping with T790M mutations. Further studies are warranted to define adequate therapeutic strategies for MET-driven resistance to EGFR TKI." @default.
• W2763344034 created "2017-10-20" @default.
• W2763344034 creator A5002994604 @default.
• W2763344034 creator A5009365878 @default.
• W2763344034 creator A5013990412 @default.
• W2763344034 creator A5031066819 @default.
• W2763344034 creator A5032393857 @default.
• W2763344034 creator A5043045128 @default.
• W2763344034 creator A5047402540 @default.
• W2763344034 creator A5050821351 @default.
• W2763344034 creator A5053712155 @default.
• W2763344034 creator A5055246540 @default.
• W2763344034 creator A5055716383 @default.
• W2763344034 creator A5058623156 @default.
• W2763344034 creator A5064889616 @default.
• W2763344034 creator A5071449669 @default.
• W2763344034 creator A5073118412 @default.
• W2763344034 creator A5079143102 @default.
• W2763344034 creator A5083786421 @default.
• W2763344034 creator A5090329560 @default.
• W2763344034 date "2017-10-09" @default.
• W2763344034 modified "2023-10-17" @default.
• W2763344034 title "Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors" @default.
• W2763344034 cites W1607191560 @default.
• W2763344034 cites W1837776460 @default.
• W2763344034 cites W1968319149 @default.
• W2763344034 cites W1980497534 @default.
• W2763344034 cites W1983159571 @default.
• W2763344034 cites W1985264867 @default.
• W2763344034 cites W1998971866 @default.
• W2763344034 cites W2014484940 @default.
• W2763344034 cites W2022146334 @default.
• W2763344034 cites W2022670843 @default.
• W2763344034 cites W2041420833 @default.
• W2763344034 cites W2049937850 @default.
• W2763344034 cites W2052378862 @default.
• W2763344034 cites W2065477010 @default.
• W2763344034 cites W2076178766 @default.
• W2763344034 cites W2093613683 @default.
• W2763344034 cites W2096198395 @default.
• W2763344034 cites W2099753997 @default.
• W2763344034 cites W2110540279 @default.
• W2763344034 cites W2111662961 @default.
• W2763344034 cites W2121260558 @default.
• W2763344034 cites W2132157071 @default.
• W2763344034 cites W2133963438 @default.
• W2763344034 cites W2134107679 @default.
• W2763344034 cites W2138089710 @default.
• W2763344034 cites W2154149901 @default.
• W2763344034 cites W2154402764 @default.
• W2763344034 cites W2166084034 @default.
• W2763344034 cites W2219125393 @default.
• W2763344034 cites W2239287815 @default.
• W2763344034 cites W2272081149 @default.
• W2763344034 cites W2300085745 @default.
• W2763344034 cites W2314173732 @default.
• W2763344034 cites W2409552123 @default.
• W2763344034 cites W2410027206 @default.
• W2763344034 cites W2526076440 @default.
• W2763344034 doi "https://doi.org/10.18632/oncotarget.21707" @default.
• W2763344034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5739624" @default.
• W2763344034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29285237" @default.
• W2763344034 hasPublicationYear "2017" @default.
• W2763344034 type Work @default.
• W2763344034 sameAs 2763344034 @default.
• W2763344034 citedByCount "25" @default.
• W2763344034 countsByYear W27633440342018 @default.
• W2763344034 countsByYear W27633440342019 @default.
• W2763344034 countsByYear W27633440342020 @default.
• W2763344034 countsByYear W27633440342021 @default.
• W2763344034 countsByYear W27633440342022 @default.
• W2763344034 countsByYear W27633440342023 @default.
• W2763344034 crossrefType "journal-article" @default.
• W2763344034 hasAuthorship W2763344034A5002994604 @default.
• W2763344034 hasAuthorship W2763344034A5009365878 @default.
• W2763344034 hasAuthorship W2763344034A5013990412 @default.
• W2763344034 hasAuthorship W2763344034A5031066819 @default.
• W2763344034 hasAuthorship W2763344034A5032393857 @default.
• W2763344034 hasAuthorship W2763344034A5043045128 @default.
• W2763344034 hasAuthorship W2763344034A5047402540 @default.
• W2763344034 hasAuthorship W2763344034A5050821351 @default.
• W2763344034 hasAuthorship W2763344034A5053712155 @default.
• W2763344034 hasAuthorship W2763344034A5055246540 @default.
• W2763344034 hasAuthorship W2763344034A5055716383 @default.
• W2763344034 hasAuthorship W2763344034A5058623156 @default.
• W2763344034 hasAuthorship W2763344034A5064889616 @default.
• W2763344034 hasAuthorship W2763344034A5071449669 @default.
• W2763344034 hasAuthorship W2763344034A5073118412 @default.
• W2763344034 hasAuthorship W2763344034A5079143102 @default.
• W2763344034 hasAuthorship W2763344034A5083786421 @default.
• W2763344034 hasAuthorship W2763344034A5090329560 @default.
• W2763344034 hasBestOaLocation W27633440341 @default.
• W2763344034 hasConcept C126322002 @default.
• W2763344034 hasConcept C142362112 @default.
• W2763344034 hasConcept C15708023 @default.
• W2763344034 hasConcept C161191863 @default.
• W2763344034 hasConcept C3017595490 @default.
• W2763344034 hasConcept C41008148 @default.

• next